For the Inventor, By the Inventor

Enter assignee name

Newark, CA, United States of America

Cellerant Therapeutics, Inc.

USPTO Granted Patents = 17

CIPO Patents = 2

EPO Patents = 5

Trademarks = 1

Forward Citations = 117

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Holger Karsunky (10 out of 11 patents)

Jagath Reddy Junutula (5 out of 37 patents)

Ying-Ping Jiang (4 out of 9 patents)

4. Vasu Jammalamadaka (3 out of 19 patents)

5. Ping Jiang (3 out of 3 patents)

6. Rob Tressler (3 out of 3 patents)

7. Julie Lynne Christensen (3 out of 5 patents)

8. Timothy C Fong (2 out of 6 patents)

9. Adrianus Geertrudis Wilhelmus Domen (2 out of 4 patents)

10. Naoya Tsurushita (1 out of 49 patents)

11. Sanjeevani Ghone (1 out of 4 patents)

12. Dmitry Borkin (1 out of 16 patents)

13. Sean W Smith (1 out of 1 patent)

14. Sylvia Degrado (1 out of 1 patent)

15. Leonard G Presta (1 out of 211 patents)

17 patents: Sort by Forward Citations

1. 11072662 - Humanized anti-CLL-1 antibodies (2021-07-27),

2. 10898580 - Isoquinolidinobenzodiazepines (2021-01-26),

3. 10723805 - Antibodies specific for CLL-1 (2020-07-28),

4. 10350218 - Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers (2019-07-16),

5. 10301394 - Antibodies that specifically bind to TIM3 (2019-05-28),

6. 9974864 - Isoquinolidinobenzodiazepines (2018-05-22),

7. 9850314 - Antibodies specific for CLL-1 (2017-12-26),

8. 9631026 - Antibodies that specifically bind to TIM3 (2017-04-25),

9. 9504694 - Isoquinolidinobenzodiazepines (2016-11-29),

10. 9371390 - Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof (2016-06-21),

11. 9163090 - Antibodies specific for CLL-1 (2015-10-20),

12. 8877495 - Methods of expanding myeloid cell populations and uses thereof (2014-11-04),

13. 8841418 - Antibodies that specifically bind to TIM3 (2014-09-23),

14. 8715619 - Compositions and methods for treating haematological proliferative disorders of myeloid origin (2014-05-06),

15. 8709715 - Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof (2014-04-29),

Cellerant Therapeutics is a biotechnology company focused on the discovery, development, and commercialization of innovative cellular and regenerative therapies. With a focus on using stem cells and other cellular components, Cellerant aims to address unmet medical needs in the fields of cancer treatment, immune disorders, and tissue regeneration. Through its cutting-edge research and collaborations, Cellerant Therapeutics aims to revolutionize the way diseases are treated and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

17 Patents

#31 in Newark, CA

#4,375 in California

#18,334 in US

#34,861 in the World

Newark, CA, United States of America

Cellerant Therapeutics, Inc.

Forward Citations = 117

15 inventors:

Holger Karsunky (10 out of 11 patents)

Jagath Reddy Junutula (5 out of 37 patents)

Ying-Ping Jiang (4 out of 9 patents)

4. Vasu Jammalamadaka (3 out of 19 patents)

5. Ping Jiang (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…